MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on June 14, 2007; DOI: 10.1124/mol.107.035550

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.035550v1
72/3/734    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Sukhwinder S. Lakhman
Xiaomin Chen
Vanessa M. Gonzalez-Covarrubias
Erin G. Schuetz
Javier G. Blanco
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lakhman, S. S.
Right arrow Articles by Blanco, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lakhman, S. S.
Right arrow Articles by Blanco, J. G.


Received for publication February 27, 2007.
Revised May 4, 2007.
Accepted for publication June 14, 2007.

Functional characterization of the promoter of human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating induction of CBR1 by ligands of the aryl hydrocarbon receptor

Sukhwinder S. Lakhman 1, Xiaomin Chen 1, Vanessa M. Gonzalez-Covarrubias 1, Erin G. Schuetz 2, Javier G. Blanco 1*

1 State University of New York at Buffalo 2 St. Jude Children's Research Hospital

* Address correspondence to: E-mail: jgblanco{at}buffalo.edu

Abstract

Human carbonyl reductase 1 (CBR1) metabolizes a variety of substrates including the anticancer doxorubicin, and the antipsychotic haloperidol. The transcriptional regulation of CBR1 has been largely unexplored. Therefore, we first investigated the promoter activities of progressive gene-reporter constructs encompassing up to 2.4 kb upstream the translation start site of CBR1. Next, we investigated whether CBR1 mRNA levels were altered in cells incubated with prototypical receptor activators (e.g. dexamethasone and rifampicin). CBR1 mRNA levels were significantly induced (5-fold) by the ligand of the aryl hydrocarbon receptor (AHR) {beta}-naphthoflavone. DNA sequence analysis revealed two xenobiotic response elements (-122XRE, and -5783XRE) with potential regulatory functions. CBR1 promoter constructs lacking the -122XRE showed diminished (9-fold) promoter activity in AHR proficient cells incubated with {beta}-naphthoflavone. Fusion of -5783XRE to the -2485CBR1 reporter construct enhanced its promoter activity after incubations with {beta}-naphthoflavone by 5-fold. Furthermore, we tested whether the potent AHR ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induced Cbr1 expression in Ahr+/- and Ahr-/- mice. TCDD induced hepatic Cbr1 mRNA (TCDD: 2-fold) and Cbr1 protein levels (TCDD: 2-fold) in Ahr+/- mice as compared to vehicle-injected controls. In contrast, no significant Cbr1 mRNA and Cbr1 protein induction was detected in livers from Ahr-/- mice treated with TCDD. These studies provide the first insights on the functional characteristics of the human CBR1 gene promoter. Our data indicate that the AHR pathway contributes to the transcriptional regulation of CBR1.


Key words: Quinone oxidoreductase, Regulation - physiological, Regulation - transcriptional, Regulation - xenobiotic


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
N. Kassner, K. Huse, H.-J. Martin, U. Godtel-Armbrust, A. Metzger, I. Meineke, J. Brockmoller, K. Klein, U. M. Zanger, E. Maser, et al.
Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver
Drug Metab. Dispos., October 1, 2008; 36(10): 2113 - 2120.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics